Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild10th March 2017 - 4:59 pm
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that further to the announcement made earlier today entitled “Accelerated Bookbuild for the Issue of Equity”, the accelerated Bookbuild, which was oversubscribed, has now closed.
The Company has raised a total of £4.1 million (before expenses) by way of an issue of 7,884,623 new Ordinary Shares (the “New Share Placing”) at the Placing Price of 52p (the “New Placing Shares”).
£4.1 million (before expenses) raised for the Company via a placing of New Placing Shares, which are EIS and VCT qualifying;
- Major existing and new institutional investors have participated in this New Share Placing; and
- ImmuPharma has raised these additional funds via the Bookbuild in order to:
– support further investment in ImmuPharma’s earlier stage portfolio and in particular its P140 peptide platform.